EGFR and colorectal carcinoma: Activating mutations in RAS other than the KRAS exon 2 mutation have also been studied to answer the heterogenous clinical response in terms of poor response to the EGFR-directed therapy in patients with CRC harboring the wild KRAS exon 2.